SCHEMBL150406

SCHEMBL150406

N/C(=N\O)c1nonc1N

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 4/20 0.55
BTK Q06187 2/20 0.55
PLEKHA1 Q9HB21 1/20 0.55
KMT2A Q03164 2/20 0.53
RAB9A P51151 7/20 0.46
NPC1 O15118 6/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
GAA P10253 3/20 0.46
ALDH1A1 P00352 2/20 0.46
IDO1 P14902 2/20 0.46
POLB P06746 1/20 0.46
PKM P14618 6/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MAPT P10636 1/20 0.43
NFKB1 P19838 2/20 0.42
NFKB2 Q00653 2/20 0.42
RELA Q04206 2/20 0.42
MEN1 O00255 1/20 0.42
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL122211 1.00 AKT1 (0.55) AKT1BTKPLEKHA1KMT2ARAB9A
SCHEMBL14592141 1.00 AKT1 (0.55) AKT1BTKPLEKHA1KMT2ARAB9A
Hydrochloric Acid SCHEMBL20983704 0.98 AKT1 (0.58) AKT1BTKPLEKHA1KMT2ARAB9A
SCHEMBL5350096 0.82 KMT2A (0.53) AKT1BTKPLEKHA1KMT2ARAB9A
SCHEMBL14592144 0.82 KMT2A (0.53) AKT1BTKPLEKHA1KMT2ARAB9A
SCHEMBL22672833 0.80 KMT2A (0.51) AKT1BTKPLEKHA1KMT2ARAB9A
SCHEMBL22063459 0.80 KMT2A (0.56) AKT1BTKPLEKHA1KMT2ARAB9A
SCHEMBL10181686 0.77 KMT2A (0.49) AKT1BTKPLEKHA1KMT2ARAB9A
SCHEMBL122210 0.76 AKT1 (0.49) AKT1BTKPLEKHA1KMT2ARAB9A
SCHEMBL21188350 0.76 AKT1 (0.37) AKT1BTKPLEKHA1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3389783-B1 NOVEL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-07-03 EP disclosed
EP-3389783-B1 NOVEL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-07-03 EP disclosed
US-20240173303-A1 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase INCYTE HOLDINGS CORPORATION 2024-05-30 US disclosed
US-20240158385-A1 NOVEL COMPOUNDS Cerevance, Inc. 2024-05-16 US disclosed
EP-2911669-B1 SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER UNIV CHICAGO (US) 2024-04-10 EP disclosed
EP-4288433-A1 NOVEL COMPOUNDS Cerevance, Inc. (US) 2023-12-13 EP disclosed
CN-116981665-A Novel compounds 思瑞万斯公司 2023-10-31 CN disclosed
US-11518771-B2 Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-12-06 US disclosed
CN-110407765-B 1,2,5-oxadiazole derivative, preparation method and medical application thereof 上海挚盟医药科技有限公司 2022-12-06 CN disclosed
EP-3600299-B1 NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME LLC (US) 2022-11-30 EP disclosed
EP-2315756-A2 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE Incyte Corporation (US) 2011-05-04 EP disclosed
US-20100015178-A1 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION 2010-01-21 US disclosed
WO-2010005958-A2 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2010-01-14 WO disclosed
WO-2010005958-A2 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2010-01-14 WO disclosed
EP-1879573-A4 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORP (US) 2009-07-08 EP disclosed
EP-1879573-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME Incyte Corporation (US) 2008-01-23 EP disclosed
US-7157476-B2 Aminofurazan compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-01-02 US disclosed
US-7157476-B2 Aminofurazan compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-01-02 US disclosed
US-20060258719-A1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION 2006-11-16 US disclosed
WO-2006122150-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION (US) 2006-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240173303-A1 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase IDO1, IDO2, INMT AKT1 2573/4885BTK 3274/4885PLEKHA1 2954/4885
US-20240158385-A1 NOVEL COMPOUNDS KCNK3, KCNA4, KCNK13 AKT1 1636/4885BTK 1110/4885PLEKHA1 3622/4885
US-20100015178-A1 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, INMT AKT1 2573/4885BTK 3274/4885PLEKHA1 2954/4885
US-20060258719-A1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same IDO1, IDO2, INMT AKT1 2938/4885BTK 3338/4885PLEKHA1 4565/4885
US-11518771-B2 Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate ALKBH5, KDM5C, KDM5B AKT1 3946/4885BTK 2208/4885PLEKHA1 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.